Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The influence of the age of adults with sickle cell disease on the uptake, utilization and efficacy of Hydroxyurea
source: American Society of Hematology
year: 2017
authors: Cynthia Sinha, Nitya Bakshi, Diana Ross, Lakshmanan Krishnamurti
summary/abstract:Despite the efficacy of Hydroxyurea (HU) in decreasing morbidity and mortality in adults with sickle cell disease (SCD) the uptake of and adherence with HU is poor, probably as the result of a combination of both physician and patient related factors. Lack of knowledge about HU, doubts regarding effectiveness, concerns over side effects and unrealistic expectations from HU treatment have been previously identified as barriers to the wider uptake of HU by the patient. Since approval of HU for SCD by the FDA in 1998, there has been a progressive increase of the use of HU in SCD. Changes in approach and practice over this time may have impacted the attitude towards HU of patients of different ages differently. The impact of patients’ age on the uptake and utilization of HU has not been studied. We investigated the impact of age on the attitudes of adult patients towards the purpose, side effects, associated risks and benefits of taking HU.
Methods: We conducted qualitative interviews with adult SCD patients from a geographically diverse population recruited from national conferences and local SCD clinics. Data were gathered as part of a larger study of decision making regarding disease modifying therapies for SCD and development of a decision- aid tool for patients involving these disease-modifying therapies. We used a semi-structured open-ended interview guide to collect data. Audio recordings were transcribed verbatim. Transcripts were coded using qualitative content analysis with NVivo 11. We sought to understand attitudes of adult patients with SCD towards available treatment options. We then focused our analyses specifically on attitudes towards HU as a model for how SCD patients viewed their disease and treatment options. We also sought to interrogate differences in attitudes among patients who reached adulthood, before and after the general adoption of hydroxyurea as a treatment option for SCD.
Results: Age of the 95 participants ranged from 18 years to 67 years old. Female = 71. While approximately 50% of all participants reported that they were currently taking HU, younger participants were more likely to be currently taking HU than the older participants (p = .05). Seventy percent of the younger adults (Age 18-30) reported they were currently taking HU as compared to 41% of the older adults (Age 31-67) [table 1]. Younger participants were more likely to report that the decision to accept a physician recommendation to start HU was made by their parent, though some participants decided to start HU as a young adult. Younger participants understood the purpose of HU as intended to improve “blood counts” thereby decreasing crises and hospital stays. They were hopeful that HU would help and thus focused on the potential for successfully managing SCD complications rather than on the side effects from HU. For those who decided to start as young adults, they offered positive accounts in regards to the decision to start HU and maintain the treatment.
organization: Emory University School of Medicine, Atlanta, GA; Children's Healthcare of Atlanta, Emory University, Atlanta, GA; Emory Healthcare, Atlanta, GAread more
+myBinderRelated Content
-
American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic PainObjective: These evidence-based guideli...
-
Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
-
Effort set to help sickle cell patients manage medsVanderbilt University Medical Center is ...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
SCDAA News Advisory: Partial Hold on Gene Therapy TrialOn December 20, the FDA placed a partial...
-
Sickle Cell Disease: After Years of Neglect Some Promise for SufferersIt’s Black History Month, when the nat...
-
New Sickle Cell Disease Research Shows Improved Patient OutcomesEmerging therapies and promising new ins...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.